Market research
EH3A.F Amarin Corporation plc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 10.75
- Dividend yield
- Not available
- Beta
- 1.39
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- US0231112063
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 10.75
- Dividend yield
- Not available
- Beta
- 1.39
About
About Amarin Corporation plc
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EH3A.F discussion.
5 years, 5 months ago
Amarin Corporation plc is currently in a long term downtrend where the price is trading 23.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Amarin Corporation plc's total revenue rose by 16.7% to $167M since the same quarter in the previous year.
Its net income has dropped by 30.3% to $5M since the same quarter in the previous year.
Finally, its free cash flow fell by 312.1% to $-38M since the same quarter in the previous year.
Based on the above factors, Amarin Corporation plc gets an overall score of 2/5.